Skip to main content

Table 3 Compensatory changes in virus genotypes within 96 weeks of follow-up therapy.

From: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Group Patient ID Protease mutations at start of therapy Time of therapy failure Time of 2nd genotype Protease mutations after therapy failure
A #1 L10FL, K20I, M36I, M46I, I50V, I54IV, L63P, L76V Week 48 Week 144 L10F, V11I, I13V, K20R, V32I, L33F, M36I, M46I, I47V, I54M, L63P, A71V, G73S, I84V, L90M
  #2 L10V, M46I, I47V, L63P, A71V, L76V, V77I Week 12 Week 48 L63P, V77I
(therapy interruption)
  #4 L10V, K20RK, M36I, M46I, L63P, L76V, L90M Week 12 Week 24 L10V, K20R, M36I, M46I, F53L, L63P, I84IV, L90M
  #22 L10I, L33F, M46L, I54V, L63P, A71I, L76V, V77I, V82A, L90M Week 12 Week 48 L10I, L33F, M46L, F53L, I54V, L63P, A71T, G73S, V77I, V82A, L90M
B #8 K20R, V32I, M46I, L76V, V82A Week 48 Week 48 K20R, V32I, M36I, M46I, F53FL, L76V, V82A, L90LM
  #9 L10I, L24I, L33F, M46I, I54V, L63P, A71V, L76V, V82A Week 12 Week 24 L10I, L24I, L33F, M46I, F53L, I54V, L63P, A71V, L76V, V82A, I84V
  #10 L10IV, K20I, M36I, M46I, I47V, F53L, L63P, A71V, G73 D, L76V, I84V, L90M Week 12
compliance
Week 48 L10V, K20I, L33I, M36I, M46I, I47V, F53L, L63P, A71V, G73 D, L76V, I84V, L90M
  #27 L10I, M46I, I47V, L63P, A71V, L76V, L90M Week 48 Week 48 L10I, M46I, I47V, L63P, A71V, L76V, I84V, L90M
C #6 L10V, L33F, M46L, I54V, A71V, L63P, A71V, L76V, V82A Week 12 Week 96 L10V, K20R, L33F, M36I, M46L, I54V, A71V, L76V, V82A
  #23 L10FIRV, L33F, I54MV, D60E, L63P, A71V, L76V, V82F Week 12 Week 24 L10FIRV, L33F, I54MV, D60E, L63P, A71T/V, L76V, V82F
  1. Compensatory changes in virus genotypes within 96 weeks of follow-up therapy. Patients with failing therapies within the 96 weeks received a second resistance testing. While L76V was still present in patients receiving L76V-selecting drugs, it was then absent in patients without these drugs (new detected mutation are underlined). Therapy failure in group B was noticeable associated with an additional establishment of the protease mutation L90 M.